Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.
Block Listing Application to AIM
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics announces application has been made to AIM for a block listing of 6,613,808 ordinary shares of 10 pence each in the Company ("Ordinary Shares"). This will be used to facilitate the admission of shares to trading following the exercise of options granted under the following two share schemes:
· The EMI Scheme - 113,808 Ordinary Shares
· The LTIP/ESOS Scheme - 6,500,000 Ordinary Shares
The Ordinary Shares will be issued from time to time pursuant to the Company's existing plans including outstanding options already issued but not yet exercised to the employees of the Company. New Ordinary Shares issued following option exercises and admitted to trading under the block admission will rank pari passu in all respects with the existing Ordinary Shares.
The block listing is expected to become effective on 26 April 2024. The Company will continue to make six-monthly announcements of the utilisation of the block admission, in line with its obligations under AIM Rule 29.
At the time of this announcement, Avacta has 359,042,104 Ordinary Shares in issue. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Results:
Forty patients (median age 65 years, range 30-79), with median 3 prior lines of therapy (range, 0-7) received escalating AVA6000 doses from 80mg/m2 (51 mg/m2 doxorubicin; molar equivalent, 0.675) to 385 mg/m2 (260 mg/m2 doxorubicin equivalent). Tumor types included soft tissue sarcoma (30%), colorectal cancer (27.5%), pancreatic cancer (20%), cancers of the biliary tract (7.5%). The safety profile was favorable, the most frequent adverse events (any grade) being fatigue (50%), alopecia (42.5%), and nausea (32.5%), with rare grade 3-4 hematologic toxicities of neutropenia (7.5%), anemia, thrombocytopenia, and WBC decreased (5% each). Grade 3 non-hematologic toxicities included mucositis, fatigue and hematemesis (n=1 each). No grade 4 non-hematologic toxicities were reported. Two DLTs were observed of grade 2 cardiac failure (120 mg/m2; LVEF decrease 61 to 39%) and grade 4 neutropenia/ thrombocytopenia (200 mg/m2). AVA6000 distributes rapidly with a t1/2 of 45 min. The Cmax of released doxorubicin was reduced as compared to standard dose doxorubicin (range 78-93% reduction) across dose cohorts. Tumor biopsy data demonstrate concentration of doxorubicin in the TME of mean 860 ng/gm (range 76-2310 ng/gm, n=9). In contrast, blood samples taken with the biopsy demonstrate a circulating free doxorubicin of 8.3 ng/ml (range 2.4-15.9), indicating concentration of doxorubicin in the tumor relative to plasma. Using RECISTv.1.1, one PR (-65%) with duration of 6 months was observed in a patient with undifferentiated pleomorphic sarcoma at 160 mg/m2, and a mixed response in a patient with angiosarcoma (SLD -22%) at 200 mg/m2. The disease control rate was 50%, at 12 wks. In each case, SD > 4 months or PR was associated with high FAP enzyme activity in the on-study tumor biopsy compared to observed disease progression as best response (n=6).
RNS...It WORKS...!
Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented:
"We are extremely pleased with the continued excellent progress of AVA6000 in the Phase 1a dose escalation study. These emerging data clearly demonstrate that the pre|CISION™ peptide drug conjugate platform is functioning in the way it was designed and is capable of targeting the release of a cancer therapy to the tumor. Targeted therapy that spares healthy tissues is a holy grail of oncology drug development and we believe we have a unique platform to target FAP-rich tumor tissues to deliver significantly better outcomes for patients and substantial value to our shareholders.
"The continuing validation of the pre|CISION™ platform we are seeing in the clinic underlines our confidence in the significant opportunity to apply pre|CISION™ to a range of warheads, including those much more potent than doxorubicin.
We are now in a very strong position to deliver significant clinical and commercial milestones relating to AVA6000 and the wider pre|CISION™ platform, and we are looking forward to providing a further detailed update on the clinical trial at the American Association for Cancer Research meeting in April."
Fingers in all kinds of pies...!
"Avacta and Mologic develop a breakthrough test for malaria, capable of identifying chloroquine-resistant strains, heralding a new era in personalized treatment."
Your on form Bella...!
“Affy-“ comes from Latin, meaning trust, relationship, and marriage, and signifies the relationship and merge between Daewoong Pharmaceutical's platform and Avacta's platform.
I think AS needs a bit of Affy with his shareholders..!
The Windows has closed..!
Rns on its way ..imho
We are writing to inform you that Avacta Group Plc has announced a new Retail Offer. As an existing shareholder you are entitled to take part in the offer, and you can find more details on the Corporate Actions page on your account. To do this, log in and go to “portfolio > corporate actions”, then click on ''Response Required''.
Please note that the Retail Offer will be conducted through a process known as an “accelerated bookbuild”, which means that the offer will have a very short deadline, often closing on the same day that it is announced.
Accordingly, if there is no Corporate Action event present on your account then it is likely that the window for election has closed. A corporate action notification will not be added to the “document history” section of your account.
Therefore, should you wish to participate, you should log in and view the details of this Corporate Action event as soon as possible. You should also note that the offer may also close early if it is oversubscribed.
Thank you for investing with ii.
interactive investor
Doubt be so Dumb...
This thread starts at 07.29 by DOGS80....Anyone know if he managed to sort this?
And 3 minutes later before half the normal folk are awake....
estura...."Morning Dogs80, the Q&A is being planned for w/c 26 February. I understand AS has committed to doing it with a specific date being arranged for that week."
Absolute ...BULLs1ht you are being conned...!
"Morning Dogs80, the Q&A is being planned for w/c 26 February. I understand AS has committed to doing it with a specific date being arranged for that week."
Everyone having a hissy from some anonymous poster on a BB .
Jesus get real....!
That's like believing Wyndrum is invested in AVACTA.